Table 5

Predicted lornoxicam/phenprocoumon interactions

	Lornoxicam (inhibitor)	(S)-Phenprocoumon (substrate)	Lornoxicam (substrate)	rac-Phenprocoumon (inhibitor)
Therapeutic concentration (μM)	[I] = 3^5-a	[S] = 0.018^5-b	[S] = 3^5-a	[I] = 0.053^5-c
K _m (μM)		0.6^5-d	12
K _i (μM)	12			1.2
f _h		0.97^5-e	1^5-a
f _m		0.60^5-e	0.9^5-a
[I]/K _i	0.25		0.044
Percent inhibition	19.5		3.4
R	0.8		1
R _c	1.13		1
R _observed	1.24^5-b		?^5-f

Drug/drug interactions were predicted as described in the text. The therapeutic concentration describes the concentration expected in the cytosol of the hepatocyte under therapeutic conditions. These values were derived as described in the text. Percent inhibition,R, and R_c were calculated as described in the text. R_observed indicates the degree of change in AUC_SS or C_SS in a clinical interaction study.

↵5-a Skjodt and Davies, 1998.
↵5-b Masche et al., 1999b.
↵5-c Kitteringham et al., 1984.
↵5-d Jones et al., 1996.
↵5-e Toon et al., 1985.
↵5-f no clinical data available.